← All trials
NCT04345406
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- Dec 1, 2029
- Completion date
- Dec 1, 2029
- First posted
- Apr 14, 2020
- Last posted
- Apr 14, 2020
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversityReponsible party - principal investigator
- Tanta UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.